Kornimate/medical-research-clean huggingface dataset:
one year clinical evaluation of ips empress cad versus polished celtra duo ceramic laminate veneers

Conditions: Tooth Discoloration; Tooth Fractures; Diastema

Summary: when restoring teeth with ips empress laminate veneers, fracture of restorations may occur. so, material with higher mechanical properties is required. celtra duo is a new material with glass ceramics infiltrated by 10% zirconia particles which increase the fracture resistance of the material.


Eligibility criteria:
inclusion criteria: all subjects are required to be: 1. from 18-50 years old, be able to read and sign the informed consent document. 2. have no active periodontal or pulpal diseases, have teeth with good restorations 3. psychologically and physically able to tolerate conventional dental procedures 4. patients with teeth problems indicated for laminate veneer: 1. discoloration 2. fracture not involving more than 50% enamel loss 3. mild malposition 4. diastema 5. enamel fluorosis 6. stained or defective restorations 5. able to return for follow-up examinations and evaluation exclusion criteria: 1. patient with post and core endodontically treated teeth 2. patient with fractured teeth of more than 50% enamel loss 3. patients with poor oral hygiene and motivation 4. pregnant women's 5. patients in the growth stage with partially erupted teeth 6. psychiatric problems or unrealistic expectations 7. lack of opposing dentition in the area of interest 8. patients involved in contact sports 9. teeth with deep discoloration
comparing patient satisfaction with pataday or bepreve

Conditions: Eye Allergies

Summary: the purpose of this study is to compare patient satisfaction with pataday (olopatadine hydrochloride 0.2%) one daily (qd) and bepreve (bepotastine besilate ophthalmic solution 1.5%) two times a day (bid).

5 week randomized study with 15 subjects using pataday qd for 2 weeks, and the other 15 subjects using bepreve bid for 2 weeks. following a one-week washout period, the two groups are given the opposite test article (ta) for 2 weeks. subjects to complete daily diary regarding effects of drug and are seen in clinic for 3 exams.

Eligibility criteria:
inclusion criteria: * be male or female subjects of any racial/ethnic group. * be at least 18 years of age or older. * have a diagnosis of allergic conjunctivitis with active symptoms, with no concurrent ocular allergy associated conditions and no plans to have ocular surgery during study period. * willing and able to return for all required visits and follow instructions from investigator and staff. * able to self-administer test article (ta) or have a caregiver available to instill all doses of ta. * if a woman, capable of becoming pregnant, agrees to have pregnancy testing performed at screening (must be negative) and agrees to use a medically acceptable form of birth control (intrauterine device, birth control pill, patch or subcutaneous implant, condoms, diaphragm, and abstinence) throughout the study duration and for at least one week prior to and one week after completion of the study. women considered capable of becoming pregnant include all females who have experienced menarche and who have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). * sign and date the informed consent form approved by an institutional review board (irb)/independent ethics committee (iec). * be willing/able to return for all required study visits, to follow instructions from the study investigator and his/her staff, and to complete and return the screening and subject diaries. exclusion criteria: * have known hypersensitivity to bepreve or pataday or any of their components. * are actively taking steroids or antihistamines during the study or within 7 days prior to enrolling in the study. * are pregnant, planning to become pregnant, or nursing/lactating. * have a known history of alcohol or drug abuse. * participated in a study of an investigational drug or device within the past 30 days prior to enrolling in the study. * have a presence of an active ocular infection (bacterial, viral or fungal), positive history of an ocular herpetic infection, or preauricular lymphadenopathy at any visit. * have any significant illness {eg: any autoimmune disease, or severe cardiovascular disease (including arrhythmias)}that the investigator feels could be expected to interfere with the subject's safety or study parameters and/or put the subject at anyh unnecessary risk.

Keywords: eye itching allergies
comparison of the efficacy of peripheral nerve blocks in major open gynaecological cancer surgery

Conditions: Postoperative Pain; Postoperative Complications; Analgesia; Regional Anesthesia Morbidity

Summary: the aim of this prospective randomized study was to compare the effectiveness of subcostal transversus abdominis plane block or rectus sheath block applied in addition to posterior transversus abdominis plane block for postoperative analgesia in major gynecological cancer surgeries. the main question(s) it aims to answer are: \[is subcostal transversus abdominis plane block more effective in postoperative analgesia? \] \[is there a difference in pain scores at 24 hours after surgery? \] since pain scores within the first 24 hours after surgery will be evaluated, participants will be asked to give a value between 0 and 10 at certain time periods.

this prospective, randomized study was conducted at başakşehir çam and sakura city hospital in accordance with the declaration of helsinki. after ethics committee approval (decision no: 2023-596, date: 22.11.2023) and written consent from all patients, the study was conducted according to consolidated standards of reporting trials (consort) guidelines. in the study, which included a total of 50 patients, the patients were divided into two groups: subcostal transversus abdominis plane block (stapb) or rectus sheath block (rsb). postoperative 24-hour vas values, opioid demand and administration amounts in intravenous patient-controlled analgesia, presence of nausea and vomiting, surgical complications and length of hospital stay were evaluated (6th hour, 12th hour, 24th hour).

Eligibility criteria:
inclusion criteria: * \>18 years * asa ii-iii exclusion criteria: * those who are allergic to local anesthetics * bmi\> 40 kg/m2 * those with chronic pain * those with a history of previous abdominal surgery * patients who refuse the use of postoperative patient-controlled analgesia
the influence of bariatric surgery on patients with obstructive sleep apnea (osa)

Conditions: Overweight; Obstructive Sleep Apnea

Summary: obesity is a very important risk-factor in obstructive sleep apnea (osa) and other sleep breathing disorders in patients with extreme bmi. candidates for bariatric surgery have a high osa prevalence, ranging from 60-83%. the characteristics of patients with sleep apnea that were evaluated for bariatric surgery and had a full overnight polysomnography (psg) screening for osa were described and it was found that a very high prevalence (77.2%) for osa in all subjects evaluated, regardless of pre-operative risk for osa. a post-bariatric surgery psg was not a part of this study. the investigators would like to demonstrate the impact of bariatric surgery on osa as a function of time.


Eligibility criteria:
inclusion criteria: * all candidates for bariatric surgery over 18 yrs of age exclusion criteria: * patients that underwent any osa surgery in the past * patient had any bariatric surgery in the past * patients with copd * patients with chd * patients who have / had cancer that received chemotherapy or radiotherapy

Keywords: bariatric surgery sleep apnea overweight
electrical activity of the diaphragm and respiratory mechanics during nava

Conditions: Work of Breathing; Lung Transplantation; Neurally Adjusted Ventilatory Assist; Ventilator-Induced Lung Injury

Summary: protective ventilatory strategy should be applied to reduce both ventilator-induced lung injury (vili) and ventilator-induced diaphragm dysfunction (vidd) after lung transplantation (ltx). neurally adjusted ventilatory assist (nava) is an assisted ventilation mode in which respiratory support is coordinated by the electrical activity of the diaphragm (eadi). aim of the study is to assess the physiological relationship between neural respiratory drive as assessed by eadi and tidal volume, driving pressure and mechanical power, at different levels of ventilatory assist, in the absence of pulmonary vagal afferent feedback.

lung transplantation (ltx) is an important treatment option for select patients with end-stage pulmonary disease. in the early period following ltx a protective ventilatory strategy should be applied to reduce both ventilator-induced lung injury (vili) and ventilator-induced diaphragm dysfunction (vidd) after lung tranplantation (ltx). neurally adjusted ventilatory assist (nava) is an assisted ventilation mode in which neural inspiratory activity is monitored through the continuous recording of electrical activity of the diaphragm (eadi) and then used to coordinate the respiratory support delivered by the ventilator. nava, because of its intrinsic properties (proportionality between respiratory drive and level of assist, prevention of diaphragm atrophy), could allow the aforementioned ventilatory strategy, however it may require the integrity of the pulmonary vagal afferent feedback in order to avoid volutrauma. so, the aim of the study is the evaluation of the physiological relationship between eadi and tidal volume, driving pressure and mechanical power, at different levels of ventilatory assist, in the absence of pulmonary vagal afferent feedback, in early post-operative period after ltx.

Eligibility criteria:
inclusion criteria: * age \> 18 y.o. * admission to icu for post-operative monitoring after ltx * presence of spontaneous breathing activity * sedation titrated to a target rass between 0 and -2 * written informed consent obtained exclusion criteria: * contraindication to nasogastric tube insertion (gastroesophageal surgery in the previous 3 months, gastroesophageal bleeding in the previous 30 days, history of esophageal varices, facial trauma) * increased risk of bleeding with nasogastric tube insertion, due to severe coagulation disorders and severe thrombocytopenia ( i.e., inr \> 2 and platelets count \< 70.000/mm3) * severe hemodynamic instability (noradenaline \> 0.3 μg/kg/min and/or use of vasopressin) * postoperative extracorporeal respiratory support (ecmo) * pre-operative reconditioning of the transplanted lungs by means of ex-vivo lung perfusion (evlp) * lung retransplantation * failure to obtain a stable eadi signal

Keywords: lung injury ventilator-induced lung injury neurally adjusted ventilatory assist
study evaluating the efficacy and safety of simvastatin alone compared with simvastatin plus ezetimibe in type 2 diabetic patients (0653-021)(completed)

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to determine if the addition of ezetimibe 10 mg daily to ongoing 20 mg simvastatin daily will reduce ldl cholesterol to a greater extent than increasing the dose of simvastatin to 40 mg daily in type 2 diabetics treated with thiazolidinediones (tzd).


Eligibility criteria:
inclusion criteria: * men or women age between 30 and 75 with type 2 diabetes mellitus who are treated with pioglitazone or rosiglitazone * additionally, patients must have an ldl-c \>100 mg/dl at visit 1 or prior to initiation of statin therapy exclusion criteria: * patients taking sliding scale insulin, selected lipid lowering medications, oral anticoagulants and cyclical sex hormones * patients with heart disease, kidney disease, liver disease, uncontrolled high blood pressure, and insulin dependent diabetes
efficacy of sm on postural instability and quality of life in patients with chronic non specific low back pain(cnslbp)

Conditions: Chronic Non Specific Low Back Pain

Summary: this study will give a new insight to the physiotherapy fraternity in the effects of spinal manipulation in as clinical practice, as well as the patient's community in quick re-establishment of functional ability, pain decrease, and improvement of quality of life for economic reasons. in this high opinion, application of short-term intensive spinal manipulation for non specific chronic low back pain treatment is desirable.

the protocol for group a included high velocity low amplitude thrust (hvla) to the lumbar region of the spine between l1 and l5 vertebrae.the hvla thrust will be performed with the patient side lying in a neutral.52 they take part in 12 treatment visits, 10 to 20 minutes sessions of sm over 2 weeks. light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy. the protocol for group b included sets of exercise therapy. there are three components to the exercise therapy (et) program: self education, supervised exercise visits, and home exercise. the overall objectives are to help patient's manage their lbp and prevent future lbp recurrences. total number of visits 12 (e.g., ability to perform exercises independently). outcome: patient self-report outcomes will be collected at first baseline visit and its base on the pain intensity and quality of life will be assessed by using numerical pain rating scale and euroqol questionnaire. objective outcome measures will be collected at the first baseline visit and its base on postural instability and pressure pain threshold will be assessed by using win track platform and digital algometer.

Eligibility criteria:
inclusion criteria: * 18 to 55 years of age. * both genders. * subjects diagnosed with non-specific chronic low back pain with duration of \>3 months. * low back pain intensity≥3 on 0-10 in numerical pain rating scale. exclusion criteria: * injury or surgery of spine. * congenital spinal deformity (e.g spina bifida, scoliosis, ankylosing spondylitis etc ) * lumbar radiculopathy or presenting neurological deficit. * subjects administered epidural injection. * contra-indication to manipulations-vertebral malignancy, vertebral-basilar insufficiency, bone infections, fracture.

Keywords: spinal manipulation postural instability quality of life
partially hydrolyzed whey formula in cow's milk allergic patients

Conditions: Food Allergy

Summary: cow's milk (cm) allergy is the most common food allergy in children, affecting 2-3% of infants. in formula-fed infants with cm allergy, extensively hydrolyzed or amino acid-based infant formulas are typically recommended. these formulas are expensive and not palatable. for older patients with cm allergy, the standard of care is avoidance of all cm products. the investigators cared for a cm allergic patient who was able to tolerate partially hydrolyzed whey formula (phwf), which tastes better and is less expensive than extensively hydrolyzed or amino-acid based formulas. there are likely other subjects who could similarly tolerate phwf. furthermore, it is possible that taking phwf could accelerate tolerance of cm. the investigators aim to identify characteristics of cm allergic subjects who can tolerate phwf and assess the degree to which taking phwf accelerates cm tolerance.

specifically, subjects who have cm allergy will be enrolled. the investigators will perform an oral food challenge (ofc) to phwf in each subject. subjects who pass the challenge will be placed on phwf for 2 years. subjects who do not pass the challenge will receive routine care. the investigators will perform allergy skin testing, specific ige measurement, other serologic assays, and longitudinal ofcs to profile subject characteristics in the two groups at baseline and over time.

Eligibility criteria:
inclusion criteria: * age 0.5-18 years old * positive skin prick tests (spt) or detectable serum milk specific ige and a history of an allergic reaction to milk within 6 months before study screening; or milk-specific ige level or spt highly predictive for clinical reactivity (if ≤ 2 years old, sige \>2 ku/l; if \> 2 years old, a level \>5 ku/l; spt wheal diameter ≥ 3 mm) * a clinical reaction during the cows milk oral food challenge exclusion criteria: * negative spt and undetectable milk-specific sige * unstable asthma, allergic rhinitis, or atopic dermatitis * milk-induced eosinophilic gastroenteropathy * recent reaction to partially hydrolyzed whey formula * history of severe anaphylaxis with hypotension to cows milk * participation in any interventional study for the treatment of food allergy in the 6 months prior to screening visit * inhalant allergent immunotherapy that has not yet reached maintenance dosing * inability to discontinue antihistamines for skin testing, ofc * any systemic therapy which in the judgment of the investigator could be immunomodulatory in the 12 months prior to visit 1 (xolair, rituximab, chronic steroids, etc) * investigational drug use 90 days prior to visit 1 or intention to use during study period * the presence of any medical condition that the investigator deems incompatible with participation in the trial. * unable to understand and speak english

Keywords: food allergy cows milk allergy
tracking response to antidepressants in advance of investigational trials

Conditions: Major Depressive Disorder

Summary: trait is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (ssris) and selective-norepinephrine reuptake inhibitors (snris) among individuals meeting criteria for major depressive disorder (mdd) and seeking enrollment in investigational trials.


Eligibility criteria:
inclusion criteria: * participant has signed an icf prior to any study-specific procedures being performed. * participant is male or female of age ≥ 18 years old. * participant has a diagnosis of mdd as confirmed by the mini semi-structured diagnostic interview and ≥ 14 ham-d total score. * participant is in good physical health and, in the opinion of the investigator, is a suitable candidate for treatment with an adt. exclusion criteria: * participant is pregnant, breast-feeding, or planning to become pregnant. * a history or presence of a clinically significant hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic abnormality, which in the opinion of the investigator may impact participant safety or study results. * participant has a history of any psychiatric condition other than mdd, which in the opinion of the investigator is primary, or any other psychiatric or neurologic disorder or symptom that could pose undue risk to the participant or compromise the study. * any participant who represents an acute suicidal risk in the opinion of the investigator. * moderate or severe substance use disorder within 90 days prior to screen, according to dsm-5 criteria that in the opinion of the investigator could pose undue risk to the participant, or compromise the study. * any condition that, in the opinion of the investigator, makes the participant unsuitable for the study.
evaluation of microcirculatory function and mitochondrial respiration after cardiovascular surgery

Conditions: Shock; Cardiovascular Diseases; Critical Illness

Summary: this study will examine the differences in microcirculatory function and mitochondrial respiration in patients with shock after cardiovascular surgery.

post-cardiotomy shock (pcs) occurs in up to 5% of cardiovascular surgeries and has an in-hospital mortality rate as high as 75%. it is unclear if patients with pcs despite achieving standard resuscitation goals have impairments in oxygen delivery or oxygen utilization. this study will examine the difference in microcirculatory function and mitochondrial respiration in patients with shock to better understand the driving mechanism of bioenergetic failure in patients with pcs.

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years old) * receiving elective coronary artery bypass graft (cabg) * receiving valvular surgery requiring cardiopulmonary bypass exclusion criteria: * unable to tolerate sublingual microcirculatory flow imaging (e.g., non-intubated patients dependent upon oxygen by facemask, poor mouth opening) * receiving an emergent procedure * have an actively treated malignancy * mitochondrial disorder * receiving surgery requiring deep hypothermic circulatory arrest.

Keywords: microcirculation mitochondrial respiration circulatory shock cardiovascular surgery resuscitation
injection of an autologous a2m concentrate alleviates back pain in fac-positive patients

Conditions: Low Back Pain

Summary: a cartilage degradation product, the fibronectin-aggrecan complex (fac), has been identified in patients with degenerative disc disease (ddd). alpha-2-macroglobulin (a2m) can prevent the formation of the g3 domain of aggrecan, reducing the fibronectin-aggrecan g3 complex and therefore may be an efficacious treatment. the present study was designed to determine 1) the ability of autologous concentrated a2m to relieve back pain in patients with lbp from ddd and 2) the ability of fac to predict the response to this biologic therapy. 24 patients with low back pain and mri-concordant ddd had prospective evaluation. oswestry disability index (odi) and visual analog scores (vas) were noted at baseline and at 3- and 6-month follow-up. primary outcome of clinical improvement was defined as patients with both a decrease in vas of at least 3 points and odi \>20 points. molecular discography and delayed fac analysis and injection of platelet poor plasma at the time of the procedure. patients with fact-positive assays were significantly more likely to show improvement in their vas and odi at follow-up.

objectives: a cartilage degradation product, the fibronectin-aggrecan complex (fac), has been identified in patients with degenerative disc disease (ddd). alpha-2-macroglobulin (a2m) can prevent the formation of the g3 domain of aggrecan, reducing the fibronectin-aggrecan g3 complex and therefore may be an efficacious treatment. the present study was designed to determine 1) the ability of autologous platelet poor plasma (ppp) with concentrated a2m to relieve back pain in patients with low back pain (lbp) from ddd and 2) the ability of fac to predict the response to this biologic therapy. study design/setting: prospective cohort patients: 24 patients with low back pain and mri-concordant ddd methods: all patients underwent lavage for molecular discography and delayed fac analysis and injection of autologous platelet poor plasma (ppp) rich in a2m (cytonics autologous protease inhibitor concentrate, apic) at the time of the procedure. anova with bonferonni correction for multiple comparisons was performed.

Eligibility criteria:
inclusion criteria: * 18 years of age or greater with a history of low back pain complaints primarily dictated by pain with associated sensory symptoms and/or low back pain for 6 months or more who had failed expectant management with nsaids, activity modification, and/or physical therapy. * mri that demonstrated signs of degenerative disc disease at one or more levels with a pfirrmann grade of ii to iv. * age from 18 to 65 with axial back pain of at least 6 months duration. exclusion criteria: * patients with a history of oral or injected corticosteroid medication within a three month period prior to disc injection. * chronic medical conditions associated with metabolic or inflammatory disorders (insulin-dependent diabetes mellitus, severe coronary artery disease, rheumatic or autoimmune diseases) were excluded from the study.

Keywords: biologic, alpha 2 macroglobulin a2m back pain apic fac fact